Detalhe da pesquisa
1.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Blood
; 141(13): 1584-1596, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375120
2.
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
J Med Chem
; 67(4): 2321-2336, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300987